Prognostic Utility of Total (68)Ga-DOTATATE-Avid Tumor Volume in Patients with Neuroendocrine Tumors

BACKGROUND & AIMS: Survival times vary among patients with neuroendocrine tumors (NETs)—even among those with the same site, stage, and grade of primary tumor. This makes it difficult to select treatment for patients with unresectable NETs, because some patients can survive decades without treat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Gastroenterology
Autores principales: Tirosh, Amit, Papadakis, Georgios Z., Millo, Corina, Hammoud, Dima, Sadowski, Samira M., Herscovitch, Peter, Pacak, Karel, Marx, Stephen J., Yang, Lily, Nockel, Pavel, Shell, Jasmine, Green, Patience, Keutgen, Xavier M., Patel, Dhaval, Nilubol, Naris, Kebebew, Electron
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5847442/
https://ncbi.nlm.nih.gov/pubmed/29155309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.gastro.2017.11.008
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares